
The Pharmacovigilance Risk Assessment Committee (PRAC) at the European Medicines Agency (EMA) will keep reviewing reports on pericarditis and myocarditis following vaccination with Johnson & Johnson's covid-19 vaccine. PRAC concludes that more data and investigation will be needed in order to assess whether there is a documented connection between cause and effect, according to the Danish Medicines Agency (DMA).
PRAC has further stated that it is closely monitoring thrombosis with thrombocytopenia syndrome in connection with the vaccine, but has no updates on this at the moment.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app